Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 02, 2018 07:05 ET | Source: Aptose Biosciences, Inc.

Aptose Biosciences to Present at Canaccord Genuity 38th Annual Growth Conference

SAN DIEGO and TORONTO, Aug. 02, 2018 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated therapeutics targeting the...
July 31, 2018 08:00 ET | Source: Aptose Biosciences, Inc.

Aptose to Present at the 2018 Global Congress on Oncology and Cancer

SAN DIEGO and TORONTO, July 31, 2018 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (NASDAQ:APTO) (TSX:APS), a clinical-stage company developing highly differentiated therapeutics targeting the...
July 24, 2018 07:05 ET | Source: Aptose Biosciences, Inc.

Aptose To Release Second Quarter Ended June 30, 2018 Financial Results and Hold Conference Call on August 7, 2018

SAN DIEGO and TORONTO, July 24, 2018 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (NASDAQ:APTO) (TSX:APS), a clinical-stage company developing highly differentiated therapeutics targeting the...
July 10, 2018 07:00 ET | Source: Aptose Biosciences, Inc.

Aptose Biosciences and CrystalGenomics Announce Issuance of Japanese Patent for CG-806

SAN DIEGO, TORONTO, and SEOUL, July 10, 2018 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ:APTO) (TSX:APS), today announced that the Japan Patent Office has issued...
July 09, 2018 07:00 ET | Source: Aptose Biosciences, Inc.

Aptose Biosciences to Participate at the Oppenheimer & Co. Inc. Boston Oncology Insight Summit and 1x1 Day

SAN DIEGO and TORONTO, July 09, 2018 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (NASDAQ:APTO) (TSX:APS) today announced that William G. Rice, Ph.D., Chairman, President and Chief Executive Officer...
June 29, 2018 07:00 ET | Source: Aptose Biosciences, Inc.

FDA Lifts Clinical Hold so MYC Inhibitor APTO-253 Can Return to Phase 1b Trial In Patients With Hematologic Cancers

SAN DIEGO and TORONTO, June 29, 2018 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (NASDAQ:APTO) (TSX:APS) today announced that the U.S. Food and Drug Administration (FDA) has notified the company...
June 15, 2018 08:00 ET | Source: Aptose Biosciences, Inc.

Aptose Presents New CG-806 Data at the 23rd Congress of the European Hematology Association

STOCKHOLM, Sweden and SAN DIEGO, June 15, 2018 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (NASDAQ:APTO) (TSX:APS) today announced the presentation of preclinical data demonstrating that CG-806, a...
June 14, 2018 07:05 ET | Source: Aptose Biosciences, Inc.; CrystalGenomics, Inc.

Aptose Enters Into License Agreement With CrystalGenomics to Acquire CG-806 Rights in China

SAN DIEGO and SEOUL, South Korea, June 14, 2018 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (NASDAQ:APTO) (TSX:APS) today announced that they have entered into a license agreement with...
June 05, 2018 16:05 ET | Source: Aptose Biosciences, Inc.

Aptose Biosciences Announces Results of Annual Meeting of Shareholders

SAN DIEGO and TORONTO, June 05, 2018 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ:APTO) (TSX:APS), a clinical-stage company developing highly differentiated...
June 04, 2018 07:04 ET | Source: Aptose Biosciences, Inc.

Aptose Announces Two Publications of Preclinical Data Elucidating the Anticancer Mechanism of Action of APTO-253

Identification of APTO-253 target leading to inhibition of MYC expression in AML and hypersensitivity of cancer cells with BRCA1/2 deficiencies SAN DIEGO and TORONTO, June 04, 2018 (GLOBE NEWSWIRE)...